Review
Published · Updated · 1 min read
Levosimendan in decompensated heart failure: improved cardiac and renal function
What it means for practice
Levosimendan may support cardiorenal stabilization and initiation of quadruple therapy in decompensated heart failure. Interpret this cautiously: the abstract provides no description of a comparator group or quantitative safety data.
Summary
What was studied
A study involving 48 patients evaluated the efficacy and safety of levosimendan in decompensated heart failure with reduced ejection fraction. Particular attention was given to patients with diuretic resistance or hypoperfusion. The aim was to assess the effects of treatment on cardiac and renal function and the ability to initiate quadruple therapy.
Key findings
According to the abstract, levosimendan significantly reduced N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. Improvements in left ventricular ejection fraction, global longitudinal strain, and renal function were also reported. Treatment facilitated initiation of quadruple therapy in 81.3% of patients.
Interpretation and evidence limits
The authors consider levosimendan an effective and safe addition to the management of decompensated heart failure. However, the abstract provides no magnitudes of change, confidence intervals, description of a comparator group, or adverse event rates. The components of quadruple therapy and follow-up duration are also unspecified. These details are insufficient for an independent assessment of effect size and treatment safety.
Source
-
Раннє застосування левосимендану при декомпенсованій серцевій недостатності для кардіоренальної стабілізації та ініціації квадротерапії.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
